Davita (NYSE:DVA) received a $75.00 price target from stock analysts at SunTrust Banks in a research report issued on Thursday. The brokerage currently has a “hold” rating on the stock. SunTrust Banks’ price objective suggests a potential upside of 4.31% from the company’s current price.
Several other analysts have also recently weighed in on DVA. Royal Bank of Canada reiterated a “hold” rating and issued a $64.00 price objective on shares of Davita in a research note on Wednesday, September 6th. J P Morgan Chase & Co cut shares of Davita from a “neutral” rating to an “underweight” rating in a research note on Monday, October 9th. KeyCorp reiterated a “hold” rating on shares of Davita in a research note on Tuesday, October 10th. Zacks Investment Research cut shares of Davita from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. Finally, Wolfe Research upgraded shares of Davita from a “market perform” rating to an “outperform” rating in a research note on Monday, October 23rd. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating, three have issued a buy rating and two have given a strong buy rating to the stock. Davita currently has an average rating of “Hold” and an average price target of $73.89.
Shares of Davita (NYSE:DVA) opened at $71.90 on Thursday. Davita has a 12 month low of $52.51 and a 12 month high of $72.19. The company has a quick ratio of 1.35, a current ratio of 1.40 and a debt-to-equity ratio of 1.79. The firm has a market cap of $13,151.78, a PE ratio of 20.50, a price-to-earnings-growth ratio of 14.47 and a beta of 0.97.
Davita declared that its board has approved a stock repurchase plan on Tuesday, October 10th that permits the company to repurchase $1.50 billion in outstanding shares. This repurchase authorization permits the company to purchase shares of its stock through open market purchases. Shares repurchase plans are generally an indication that the company’s leadership believes its shares are undervalued.
In related news, CEO Javier Rodriguez sold 22,532 shares of Davita stock in a transaction that occurred on Thursday, December 7th. The shares were sold at an average price of $67.48, for a total transaction of $1,520,459.36. Following the sale, the chief executive officer now directly owns 210,317 shares of the company’s stock, valued at approximately $14,192,191.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider James K. Hilger sold 5,608 shares of Davita stock in a transaction that occurred on Thursday, December 7th. The shares were sold at an average price of $69.46, for a total transaction of $389,531.68. Following the sale, the insider now directly owns 47,649 shares in the company, valued at $3,309,699.54. The disclosure for this sale can be found here. Over the last three months, insiders sold 117,937 shares of company stock worth $8,028,379. Insiders own 2.10% of the company’s stock.
Several institutional investors have recently made changes to their positions in DVA. Schroder Investment Management Group grew its holdings in shares of Davita by 769.0% during the 3rd quarter. Schroder Investment Management Group now owns 434,191 shares of the company’s stock valued at $25,387,000 after purchasing an additional 384,224 shares during the last quarter. Canada Pension Plan Investment Board grew its holdings in shares of Davita by 14.7% during the 3rd quarter. Canada Pension Plan Investment Board now owns 444,358 shares of the company’s stock valued at $26,390,000 after purchasing an additional 56,988 shares during the last quarter. Speece Thorson Capital Group Inc. grew its holdings in shares of Davita by 14.5% during the 3rd quarter. Speece Thorson Capital Group Inc. now owns 321,182 shares of the company’s stock valued at $19,075,000 after purchasing an additional 40,667 shares during the last quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH grew its holdings in shares of Davita by 1,987.3% during the 3rd quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 41,746 shares of the company’s stock valued at $2,448,000 after purchasing an additional 39,746 shares during the last quarter. Finally, Airain ltd bought a new stake in shares of Davita during the 2nd quarter valued at approximately $2,234,000. 85.18% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION WARNING: This article was first published by American Banking and Market News and is the sole property of of American Banking and Market News. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/12/22/suntrust-banks-reiterates-75-00-price-target-for-davita-dva.html.
Davita Company Profile
DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.
